Alper Ureten, Amgen VP and General Manager, sits down with PharmaBoardroom to set out his ambitions and objectives for its Biosimilars Business Unit. Ureten also reveals the strategy behind their success with biosimilars and emphasises the need for competition and high quality to foster eco-system maturity.
The key priority for my tenure is to create sustainability, both for Amgen and for biosimilars more generally within the global market.
Claire Saxton and Lauren Kriegel of Cancer Support Community, the largest professionally led non-profit network of cancer support worldwide, discuss how cancer patient and caregiver perspectives need to be better…
Paediatric oncologist Navin Pinto, MD outlines the current use and potential of CAR-T therapies in his field, including the manufacturing challenges that still need to be addressed. Dr Pinto also…
Melanie Croce-Galis, RN, MPH explains the specificities of her work as patient engagement lead for Novartis Oncology in the US market, where significant disparities in patient access to information and…
Seasoned executive Mohamed Nasser currently oversees 16 markets for Amgen across the MEA region, including its most important – Saudi Arabia. He shares some of the key skills that pharma…
PharmaBoardroom’s ten most-read executive interviews of 2021 reflect the wide scope – in terms of both geography and value chain – that our work has taken on in the past…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
See our Cookie Privacy Policy Here